ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. General Cardiovascular Medicine
Serum JKAP as a potential prognostic biomarker in acute coronary syndrome patients undergoing percutaneous coronary intervention
Provisionally accepted
Xinjing Chen1*
Jingxuan Hong2- 1Department of Cardiology, Provincial Clinical Medical College of Fujian Medical University, Fujian Institute of Cardiovascular Disease, Fujian Provincial Hospital, Fuzhou, China
- 2Department of Cardiology, Fuzhou University Affiliated Provincial Hospital, Fujian Institute of Cardiovascular Disease, Fujian Provincial Hospital, Fuzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Our previous studies revealed that JNK pathway-associated phosphatase (JKAP) knockdown facilitated atherosclerotic progression by regulating CD4+ T cell differentiation, and CD4+ T cell subtypes are dysregulated and could predict prognosis in acute coronary syndrome (ACS) patients underwent percutaneous coronary intervention (PCI). This study aimed to further investigate the correlation of JKAP with CD4+ T cell subtypes and prognosis in ACS patients underwent PCI. Methods: This study included 173 ACS patients, serum JKAP was detected before PCI and at 1 month (M1) after PCI via enzyme-linked immunosorbent assay. Short physical performance battery (SPPB) at M1 and major adverse cardiac event (MACE) data were collected. Moreover, serum JKAP in 32 healthy control subjects was detected. Results: JKAP was largely lower in ACS patients versus healthy control subjects (P<0.001), and JKAP was increased at M1 after PCI versus that before PCI in ACS patients (P<0.001). JKAP negatively correlated with T-helper (Th)17 cells (P=0.002), and tended to negatively associate with Th1 cells (P=0.060), but didn’t correlate with Th2 or T-regulatory cells. Importantly, JKAP before PCI and at M1 after PCI showed good values in predicting MACE risk by receiver operating curve (ROC) analyses [area under curve (AUC)=0.721, AUC=0.778, respectively], while relatively weaker values in predicting SPPB score <= 6 points at M1 (AUC=0.638, AUC=0.649, respectively). Multivariable analyses revealed JKAP at M1 after PCI independently predicted lower risk of MACE (P=0.045) and SPPB score <= 6 points at M1 (P=0.025). Conclusion: JKAP may serve as a prognostic biomarker in ACS patients underwent PCI.
Keywords: Acute Coronary Syndrome, Percutaneous Coronary Intervention, JKAP, CD4+ T cells, prognosis
Received: 20 May 2025; Accepted: 29 Oct 2025.
Copyright: © 2025 Chen and Hong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xinjing Chen, chenxinjingkeyan@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.